Amgen Inc

More

• Final Glance: Biotechnology companies Friday, 24 May 2013 | 6:03 PM ET

  Amgen Inc. rose$. 29 or. 3 percent, to $105.91. Biogen Idec rose $2.62 or 1.1 percent, to $235.24. Celgene Corp. fell $1.06 or. 9 percent, to $122.58.

• Midday Glance: Biotechnology companies Friday, 24 May 2013 | 1:17 PM ET

  Amgen Inc. fell$. 16 or. 2 percent, to $105.46. Biogen Idec fell$. 30 or. 1 percent, to $232.32. Celgene Corp. fell $1.47 or 1.2 percent, to $122.18.

• Early Glance: Biotechnology companies Friday, 24 May 2013 | 10:32 AM ET

  Amgen Inc. fell$. 87 or. 8 percent, to $104.75. Biogen Idec fell $2.02 or. 9 percent, to $230.61. Celgene Corp. fell$. 91 or. 7 percent, to $122.73.

• Final Glance: Biotechnology companies Thursday, 23 May 2013 | 6:03 PM ET

  Amgen Inc. rose $1.09 or 1.0 percent, to $105.62. Biogen Idec fell$. 45 or. 2 percent, to $232.62. Gilead Sciences Inc. fell$. 45 or. 8 percent, to $55.48.

• Midday Glance: Biotechnology companies Thursday, 23 May 2013 | 1:46 PM ET

  Amgen Inc. rose $1.32 or 1.3 percent, to $105.85. Biogen Idec rose$. 79 or. 3 percent, to $233.86. Celgene Corp. rose $1.03 or. 8 percent, to $124.47.

• Halozyme names David Ramsay as CFO Thursday, 23 May 2013 | 12:24 PM ET

  SAN DIEGO-- Biopharmaceutical company Halozyme Therapeutics Inc. said Thursday that it has named David Ramsay as chief financial officer, replacing Kurt Gustafson. Gustafson had been an executive at Amgen Inc. before he joined Halozyme in 2009. Halozyme said he was leaving the company to pursue other opportunities.

• Early Glance: Biotechnology companies Thursday, 23 May 2013 | 10:45 AM ET

  Amgen Inc. fell$. 78 or. 7 percent, to $103.75. Biogen Idec fell $4.46 or 1.9 percent, to $228.61. Celgene Corp. fell $2.11 or 1.7 percent, to $121.33.

• Final Glance: Biotechnology companies Wednesday, 22 May 2013 | 6:07 PM ET

  Amgen Inc. rose$. 29 or. 3 percent, to $104.53. Biogen Idec rose $1.74 or. 8 percent, to $233.07. Celgene Corp. fell$. 06 or percent, to $123.44.

• Amag slumps on Ferahame recall in Switzerland Wednesday, 22 May 2013 | 2:16 PM ET

  NEW YORK-- Shares of Amag Pharmaceuticals Inc. sank Wednesday after the company said it is taking a batch of its anemia drug Feraheme off the market following the death of a patient. THE SPARK: Amag said its partner Takeda Pharmaceutical is taking a batch of the drug off the market in Switzerland.

• Midday Glance: Biotechnology companies Wednesday, 22 May 2013 | 1:17 PM ET

  Amgen Inc. rose $1.86 or 1.8 percent, to $106.10. Biogen Idec rose $4.67 or 2.0 percent, to $236.00. Celgene Corp. rose $2.58 or 2.1 percent, to $126.08.

• Early Glance: Biotechnology companies Wednesday, 22 May 2013 | 10:50 AM ET

  Amgen Inc. rose $1.92 or 1.8 percent, to $106.16. Biogen Idec rose $5.38 or 2.3 percent, to $236.71. Celgene Corp. rose $4.10 or 3.3 percent, to $127.60.

• Immune system cancer drugs tipped to be a $35 bln market Wednesday, 22 May 2013 | 5:33 AM ET

  *Potential sales of $35 bln a year over next 10 years- Citigroup. That bullish sales forecast by analysts at U.S. bank Citigroup highlights the growing excitement surrounding so-called immunotherapy after positive results from clinical trials conducted by companies such as Bristol-Myers Squibb and Roche Holding.

• Final Glance: Biotechnology companies Tuesday, 21 May 2013 | 8:50 PM ET

  Amgen Inc. rose $2.06 or 2.0 percent, to $104.24. Biogen Idec rose $6.15 or 2.7 percent, to $231.33. Celgene Corp. rose$. 38 or. 3 percent, to $123.50.

• Midday Glance: Biotechnology companies Tuesday, 21 May 2013 | 1:16 PM ET

  Amgen Inc. rose $1.72 or 1.7 percent, to $103.90. Biogen Idec rose $6.90 or 3.1 percent, to $232.08. Celgene Corp. fell$. 27 or. 2 percent, to $122.85.

• Early Glance: Biotechnology companies Tuesday, 21 May 2013 | 10:36 AM ET

  Amgen Inc. rose $2.04 or 2.0 percent, to $104.22. Biogen Idec rose $5.56 or 2.5 percent, to $230.74. Celgene Corp. rose $1.03 or. 8 percent, to $124.15.

• Lightning Round: CarMax, Asbury Automotive & More Monday, 20 May 2013 | 6:43 PM ET

  

  It's time for the Lightning Round. Cramer makes the call on viewer favorites.

• Final Glance: Biotechnology companies Monday, 20 May 2013 | 6:04 PM ET

  Amgen Inc. fell $3.45 or 3.3 percent, to $102.18. Biogen Idec fell $1.67 or. 7 percent, to $225.18. Celgene Corp. fell $1.79 or 1.4 percent, to $123.12.

• Midday Glance: Biotechnology companies Monday, 20 May 2013 | 1:16 PM ET

  Amgen Inc. fell $3.37 or 3.2 percent, to $102.26. Biogen Idec fell$. 36 or. 2 percent, to $226.49. Celgene Corp. fell $1.18 or. 9 percent, to $123.73.

• Early Glance: Biotechnology companies Monday, 20 May 2013 | 10:31 AM ET

  Amgen Inc. fell $1.36 or 1.3 percent, to $104.28. Biogen Idec rose $5.05 or 2.2 percent, to $231.90. Celgene Corp. fell$. 33 or. 3 percent, to $124.58.

• Final Glance: Biotechnology companies Friday, 17 May 2013 | 6:03 PM ET

  Amgen Inc. rose$. 66 or. 6 percent, to $105.63. Biogen Idec fell $1.14 or. 5 percent, to $226.85. Celgene Corp. rose $1.43 or 1.2 percent, to $124.91.